Achiko Logo cropped.jpg
Achiko AG – Investor Briefing
July 07, 2022 15:22 ET | Achiko AG
ZURICH, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF, SIX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a...
Achiko Logo cropped.jpg
Achiko AG Announces Annual Results for the Year Ended December 31, 2021
June 26, 2022 19:30 ET | Achiko AG
ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended December...
Dyadic Logo Current.jpg
Dyadic to Participate in Three Upcoming Industry Events
June 09, 2022 09:09 ET | Dyadic International, Inc.
JUPITER, Fla., June 09, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Achiko Logo cropped.jpg
Achiko Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Group
May 25, 2022 07:30 ET | Achiko AG
Buranto AG Provided a USD$260,000 (CHF 250,000) Loan Facility and Existing Strategic Investor Negma Group Provided a USD$1.04 Million (CHF 1.0 Million) Loan FacilityDerek Brandt, Co-owner of Buranto...
Achiko Logo cropped.jpg
Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
May 17, 2022 07:30 ET | Achiko AG
Registered AptameX and Has Obtained a CE Mark, Allowing the Product to Be Sold in 27 Countries in the EUAptameX Has Unique Performance Advantages Over Other Rapid Tests Through its Use of DNA...
Achiko Logo cropped.jpg
AptameX Production and Commercialization Update
April 28, 2022 08:15 ET | Achiko AG
Company has commenced shipping and will book first sales in May 2022Reorganized production line able to meet stronger than expected demand for Achiko AG’s innovative DNA aptamer saliva-based rapid...
Achiko Logo cropped.jpg
Achiko AG Research Paper and Commercialization Update
February 14, 2022 07:30 ET | Achiko AG
Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as “DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for...
First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
January 06, 2022 07:00 ET | First Wave BioPharma, Inc.
No Drug-Related SAEs Reported; Topline Data Expected 1H 2022 Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on...
Achiko Logo cropped.jpg
Achiko AG Completing CHF4.85m Financing and Changes to Senior Team
December 31, 2021 07:30 ET | Achiko AG
Completing CHF 4.85 Million Placement from August 2021Board Director Christophe Laurent to RetireAppoints Adam O’Keeffe as Ad Interim Chief Financial Officer ZURICH, Switzerland, Dec. 31, 2021 ...
Achiko Logo cropped.jpg
Achiko AG Looks Back at Pivotal Year and Reaffirms Commitment to Provide Affordable and Accurate COVID-19 Testing Solution
December 23, 2021 07:30 ET | Achiko AG
2021 Was a Pivotal Year for Achiko, Marked by Seminal Developments and ApprovalsWith AptameX™, Achiko Launched an Innovative DNA Aptamer Saliva-Based Rapid Test for Covid-19 as an Affordable and...